Buy Rating for Microbix Biosystems: Strong Antigen Revenue Growth and Mid-Term Market Potential

Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Microbix Biosystms (MBX – Research Report), with a price target of C$0.80.

David Martin PhD has given his Buy rating due to a combination of factors related to Microbix Biosystems’ recent financial performance and future prospects. The company reported a notable increase in antigen revenues, which surpassed expectations by growing 5% year-over-year and 1% quarter-over-quarter, reaching $4.3 million. This growth was largely driven by Asian testing centers preparing for the spring respiratory virus season, indicating strong demand for Microbix’s products.
Despite the anticipated reduction in demand in the latter half of 2025 due to a lighter-than-expected respiratory disease burden in China, David Martin PhD remains optimistic about the company’s mid-term growth potential. The expectation is that the current inventory drawdown will be temporary, and the overall market demand will continue to support the company’s revenue growth in the coming periods. This outlook underpins the Buy rating, as the company is well-positioned to capitalize on future opportunities in the diagnostic testing market.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MBX in relation to earlier this year.